Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HUMA
stocks logo

HUMA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.132
-17.71%
--
--
-0.120
-142.86%
--
--
-0.115
-52.08%
Estimates Revision
The market is revising Downward the revenue expectations for Humacyte, Inc. (HUMA) for FY2025, with the revenue forecasts being adjusted by -28.65% over the past three months. During the same period, the stock price has changed by -9.09%.
Revenue Estimates for FY2025
Revise Downward
down Image
-28.65%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-20.66%
In Past 3 Month
Stock Price
Go Down
down Image
-9.09%
In Past 3 Month
Wall Street analysts forecast HUMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUMA is 5.40 USD with a low forecast of 3.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast HUMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUMA is 5.40 USD with a low forecast of 3.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.300
sliders
Low
3.00
Averages
5.40
High
11.00
Current: 1.300
sliders
Low
3.00
Averages
5.40
High
11.00
Benchmark
Bruce Jackson
Buy
downgrade
$14 -> $11
2025-11-13
Reason
Benchmark
Bruce Jackson
Price Target
$14 -> $11
2025-11-13
downgrade
Buy
Reason
Benchmark analyst Bruce Jackson lowered the firm's price target on Humacyte to $11 from $14 and keeps a Buy rating on the shares post the Q3 report. The firm says the Symvess Acellular Tissue Engineered Vessel launch continued to gain new accounts during the quarter. It cites Humacyte's new shares for the target drop but believes the company's customer base continues to build.
Barclays
Matt Miksic
Overweight
initiated
$3.50
2025-08-27
Reason
Barclays
Matt Miksic
Price Target
$3.50
2025-08-27
initiated
Overweight
Reason
Barclays analyst Matt Miksic initiated coverage of Humacyte with an Overweight rating and $3.50 price target. The company is in the early stages of launching Symvess in vascular trauma, which is the first of four initial indications for its acellular tissue engineered vessel, the analyst tells investors in a research note. Barclays says the initial indication addresses significant challenges and costs associated with the care of patients suffering from vascular trauma. It sees potential sales of over $600M.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$4 -> $3
2025-08-12
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$4 -> $3
2025-08-12
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Humacyte to $3 from $4 and keeps a Buy rating on the shares. The firm says the company's July sales growth suggests potential momentum.
TD Cowen
TD Cowen
Buy
downgrade
$5
2025-08-12
Reason
TD Cowen
TD Cowen
Price Target
$5
2025-08-12
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Humacyte to $3.50 from $5 and keeps a Buy rating on the shares. The firm said the Symvess launch continues to advance with 13 hospital VAC approvals now in hand up from 5 in 1Q'25. Cowen said they are encouraged by this recent improvement in commercial traction and expect sequential revenue growth throughout 2H'25 and 2026.
Benchmark
analyst
Buy
downgrade
$17 -> $14
2025-05-14
Reason
Benchmark
analyst
Price Target
$17 -> $14
2025-05-14
downgrade
Buy
Reason
Benchmark lowered the firm's price target on Humacyte to $14 from $17 and keeps a Buy rating on the shares. Humacyte launched Symvess in February and generated its first commercial product revenue during Q1, notes the analyst, who believes the company is poised to gain significant share for surgical procedures requiring vascular grafts and notes that the new product pipeline continues to move forward.
H.C. Wainwright
H.C. Wainwright
Buy
initiated
$4
2025-05-14
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$4
2025-05-14
initiated
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Humacyte Inc (HUMA.O) is -2.77, compared to its 5-year average forward P/E of -5.85. For a more detailed relative valuation and DCF analysis to assess Humacyte Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.85
Current PE
-2.77
Overvalued PE
-1.58
Undervalued PE
-10.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.68
Undervalued EV/EBITDA
-8.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
742.13
Current PS
0.00
Overvalued PS
2078.32
Undervalued PS
-594.06
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

HUMA News & Events

Events Timeline

(ET)
2025-11-12
07:03:05
Humacyte Announces Q3 EPS of 11 Cents, Below Consensus Estimate of 15 Cents
select
2025-11-10 (ET)
2025-11-10
08:20:41
Humacyte Reveals Two-Year Findings from V007 Phase 3 Trial
select
2025-10-30 (ET)
2025-10-30
08:08:12
Humacyte reveals new data publication on Symvess
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-21Benzinga
BTIG Affirms Buy Rating on Humacyte, Keeps $6 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their market endeavors.

[object Object]
Preview
6.0
11-20Benzinga
D. Boral Capital Reiterates Buy Rating on Humacyte with $25 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.

[object Object]
Preview
4.0
11-14Benzinga
Benchmark Reaffirms Buy Rating on Humacyte, Adjusts Price Target to $11

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared intelligence.

  • Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Humacyte Inc (HUMA) stock price today?

The current price of HUMA is 1.3 USD — it has increased 0.78 % in the last trading day.

arrow icon

What is Humacyte Inc (HUMA)'s business?

Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

arrow icon

What is the price predicton of HUMA Stock?

Wall Street analysts forecast HUMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUMA is 5.40 USD with a low forecast of 3.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Humacyte Inc (HUMA)'s revenue for the last quarter?

Humacyte Inc revenue for the last quarter amounts to 753.00K USD, decreased % YoY.

arrow icon

What is Humacyte Inc (HUMA)'s earnings per share (EPS) for the last quarter?

Humacyte Inc. EPS for the last quarter amounts to -0.11 USD, decreased -66.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for Humacyte Inc (HUMA)'s fundamentals?

The market is revising Downward the revenue expectations for Humacyte, Inc. (HUMA) for FY2025, with the revenue forecasts being adjusted by -28.65% over the past three months. During the same period, the stock price has changed by -9.09%.
arrow icon

How many employees does Humacyte Inc (HUMA). have?

Humacyte Inc (HUMA) has 218 emplpoyees as of December 05 2025.

arrow icon

What is Humacyte Inc (HUMA) market cap?

Today HUMA has the market capitalization of 242.52M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free